基因组编辑
遗传增强
清脆的
基因传递
基因敲除
RNA干扰
生物
计算生物学
基因
基因组
病毒载体
载体(分子生物学)
基因组工程
生物信息学
遗传学
重组DNA
核糖核酸
作者
Paul N. Valdmanis,Mark A. Kay
出处
期刊:Human Gene Therapy
[Mary Ann Liebert, Inc.]
日期:2017-01-10
卷期号:28 (4): 361-372
被引量:47
摘要
The use of recombinant adeno-associated viruses (rAAVs) ushered in a new millennium of gene transfer for therapeutic treatment of a number of conditions, including congenital blindness, hemophilia, and spinal muscular atrophy. rAAV vectors have remarkable staying power from a therapeutic standpoint, withstanding several ebbs and flows. As new technologies such as clustered regularly interspaced short palindromic repeat genome editing emerge, it is now the delivery tool-the AAV vector-that is the stalwart. The long-standing safety of this vector in a multitude of clinical settings makes rAAV a selling point in the advancement of approaches for gene replacement, gene knockdown, gene editing, and genome modification/engineering. The research community is building on these advances to develop more tailored delivery approaches and to tweak the genome in new and unique ways. Intertwining these approaches with newly engineered rAAV vectors is greatly expanding the available tools to manipulate gene expression with a therapeutic intent.
科研通智能强力驱动
Strongly Powered by AbleSci AI